Updates and Announcements

3/9/2015

JDRF is pleased to announce the 6th Annual symposium on “Frontiers in Beta Cell Biology” in partnership with the Genomic Institute of the Novartis Foundation (GNF). Dates and speakers can be found in the flyer and registration link on the GNF website as shown below.http://www.gnf.org/collaborations/jdrf/

8/27/2014

On Friday, October 10, 2014 JDRF will be hosting a public scientific workshop entitled “Defining the Early Stages of T1D” from 8:00am until 4:45pm, at the Hyatt Regency located in Bethesda, Maryland. At this event, leading scientific experts will present and discuss the current scientific understanding of the natural history of type 1 diabetes prior to the onset of symptomatic disease, inform clinical trial design, encourage the development of therapies for the early stages of type 1 diabetes, and aid regulatory decision-making.

The objectives of the workshop are to:

Garner common understanding of current data on T1D risk detection, staging, and progression

Discuss the design and optimization of intervention trials in the early stages of T1D

If you are interested in attending this workshop please send an email to stagesoft1d@jdrf.org with your full name and email address. The deadline for registration is October 3, 2014. Registration is limited and we may reach capacity before this date. Thank you for your support and we hope to see you there!

The XII International Conference on Bioencapsulation will be held in Bratislava, Slovakia, September 17-19, 2014. JDRF is supporting a focus session on Islet Encapsulation/Biomedical applications. Please click here for more details.

Diabetes Impact Award-Closed Loop Technologies: Development and Integration of Novel Components for an Automated Artificial Pancreas System (DP3) (RFA-DK-14-015)

LOIs due: Oct 24, 2014
Applications due: November 24, 2014

4/16/2014

The American Diabetes Association and JDRF will convene national and global research expertise at the Diabetes and the Microbiome Research Symposium from October 27-29, 2014 in Chicago, Illinois, USA. Click here for further details.

Pilot projects that will directly contribute to strategies, tools, or resources for the regeneration of functional nephrons

Who is eligible to apply?

Applications are accepted from both National and International institutions/ organizations.

What funds are available for P&F Projects?

Applicants may request up to $100,000 (direct + indirect costs) Total Costs for one year. The number of awards will depend upon the number, quality, duration, and cost of the applications received. Awards will be made as subcontracts from the DiaComp Coordinating and Bioinformatics Unit (CBU) at the Georgia Regents University and not directly by the NIH.

The NIDDK has launched a new RFA: Small Business Innovation Research to Develop New Therapeutics and Monitoring Technologies for Type 1 Diabetes (T1D): Towards an Artificial Pancreas (SBIR) (R43/R44) RFA-DK-13-028

The goal of the RFA is to advance research on biomarkers that are critically needed to detect early stages of diabetic complications and to serve as surrogate end-points in drug development, not only for diabetic retinopathy, but also for other diabetes complications.

The RFA uses the DP3 mechanism that allows funding for the entire project period in the first year of the grant award. Funding for the RFA is through the Type 1 Diabetes Special Funding Program. Please contact me if you have questions about the RFA.

Established T1D Clinical Research Roadmap, Paving a New Path; A White Paper sponsored by JDRF and The Helmsley Charitable Trust. Several factors have caused a shortfall in established type 1 diabetes (T1D) non-insulin clinical research, despite the fact that T1D is one of the more prevalent autoimmune diseases. New, emerging data could challenge the current thinking surrounding the potential for therapeutic interventions in people with established T1D. Based on these findings, a bolder approach to clinical research in people with established T1D is clearly warranted. Near-term clinical development opportunities in established T1D subjects are evident. Download the report.

The 20th International Conference on Bioencapsulation will take place on 9/20-24, 2012. There is an Islet Encapsulation Focus Session. Details on the Islet Encapsulation Focus Session can be found here.

6/12/2012

JDRF Mourns the Loss of Dr. Alan Permutt

JDRF is saddened by the loss of a long-time advocate, friend, and inspiring researcher, M. Alan Permutt, MD, who passed away at the age of 72 on Sunday, June 10th after a long battle with cancer. More information.

To apply for a JDRF Travel Scholarship, submit your abstract and scholarship application by March 1st. More information. Additionally, please visit the IDS website (http://www.ids2012.ca/) for more information on IDS 2012.

1/25/2012

Faculty Opportunity at The Benroya Research Institute

The Benaroya Research Institute, in Seattle WA, is recruiting an Assistant/Associate Professor with an MD, PhD, or MD/PhD degree whose research focuses on biomedical translational research. More information.

JDRF will be offering travel awards to support the attendance of JDRF-supported young investigators at FOCIS 2012. This year, FOCIS will be held from June 21-24 in Vancouver, BC. Please visit http://www.focisnet.org/FOCIS/ for further details about the meeting.

Eligibility:

PI of a JDRF Training or Career Development Award: Postdoctoral Fellowship (PF), Advanced Postdoctoral Fellowship (APF)/Transition Award, Career Development Award (CDA), or Early Career Patient-oriented Diabetes Research Awards (ECPODRA), scientific lab member of a JDRF sponsored lab working directly on a JDRF sponsored project.

The amount of the award is TBD, and may vary depending on your departure location.

Please be aware that the travel award amount may not cover the complete expenses related to the conference, and that supplementation from your JDRF grant or other sources may be necessary.

JDRF is pleased to continue this partnership with FOCIS in the support of young investigators. Should you have any questions, please contact Emily L. Klein at elklein@jdrf.org or Dr. Simi Ahmed at sahmed@jdrf.org.

12/5/2011

A Letter to all JDRF Investigators in Regards to the New JDRF Brand and Logo

We would like to share with you some exciting news about JDRF. Over the past year, JDRF has undertaken a process to evaluate the perception of our organization with our various stakeholders. This process has resulted in a number of evolutionary changes regarding how we speak about JDRF and regarding the images we use to represent JDRF. Read more

12/2/2011

The following NIDDK funding opportunity has a Detailed Budget Correction (PAR-11-349):

Purpose: to promote the development of an interdisciplinary workforce for conducting bioengineering research to develop innovative technologies for treatment of type 1 diabetes including creating integrated long term glucose regulated insulin delivery systems (artificial pancreas), beta cell or islet encapsulation for beta cell replacement therapy, and/or beta cell and autoimmunity imaging methods. This FOA will support institutional training and education programs in type 1 diabetes research for postdoctoral level researchers with backgrounds in bioengineering and/or computational sciences.

LOI Due Date: February 14, 2012

Application Due Date: March 14, 2012

11/11/2011

Additional Research Opportunities to be considered by JDRF Canadian Clinical Trial Network (JDRF CCTN)

JDRF Canadian Clinical Trial Network (JDRF CCTN) is a platform for clinical research in Southern Ontario to test new treatments and technologies for type 1 diabetes. JDRF CCTN is pleased to explore all additional research opportunities that can be implemented using the JDRF CCTN structure. These opportunities may include partnerships with additional institutions, investigators, and industry.